Zymeworks Inc. (ZYME)
Zymeworks Inc. (ZYME)
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Segment loss | NaN | -34,219 | -13,646 | NaN |
| Depreciation and amortization | NaN | 1,083 | 1,553 | NaN |
| Stock-based compensation expense | NaN | 8,850 | 6,911 | NaN |
| Change in contingent consideration | NaN | 0 | 0 | NaN |
| Impairment on ipr&d (note 6) | NaN | 0 | 0 | NaN |
| Interest income | NaN | 2,975 | 3,529 | NaN |
| Other (expense) income, net (note 12) | NaN | -302 | 315 | NaN |
| Income tax (expense) recovery, net | NaN | -270 | 1,336 | NaN |
| Net loss | -44,162 | -41,209 | -19,602 | -20,319 |
| Depreciation of property and equipment | 963 | 898 | 905 | 1,866 |
| Change in fair value of contingent consideration liability (note 15) | NaN | 0 | 0 | 0 |
| Amortization of intangible assets | 176 | 185 | 648 | 3,223 |
| Stock-based compensation expense | 6,935 | 8,850 | 6,911 | 12,273 |
| Impairment of acquired ipr&d (note 6) | NaN | 0 | 0 | 0 |
| Amortization of operating lease right-of-use assets | 1,708 | 924 | 1,031 | 1,430 |
| Amortization of debt issuance costs | 26 | NaN | NaN | NaN |
| Non-cash interest expense related to sale of royalties | 2,040 | NaN | NaN | NaN |
| Change in fair value of investments in equity instruments | NaN | 0 | NaN | NaN |
| Deferred income tax recovery | 2,200 | -1,410 | 170 | 295 |
| Unrealized foreign exchange gain | 331 | -305 | 451 | -678 |
| Accounts receivable | 36 | -24,713 | 26,721 | -53,208 |
| Prepaid expenses and other current assets | 1,726 | 5,120 | -3,267 | -8,362 |
| Accounts payable and accrued liabilities | -7,750 | 1,335 | 3,341 | -28,324 |
| Operating lease liabilities | -1,005 | -838 | -872 | -1,632 |
| Deferred revenue | -340 | -779 | -614 | -21,777 |
| Income taxes payable | -16 | -933 | 915 | -27 |
| Net cash provided used in operating activities | -45,718 | -10,259 | -31,412 | 8,666 |
| Purchases of marketable securities | 0 | 56,828 | 35,054 | 104,179 |
| Proceeds from marketable securities | 70,175 | 62,916 | 35,832 | 126,328 |
| Acquisition of property and equipment | 216 | 581 | 410 | 530 |
| Proceeds from issuance of common stock under at-the-market program and from public offerings, net of issuance costs (notes 10a) | NaN | 0 | NaN | NaN |
| Acquisition of intangible assets | 0 | 139 | 0 | 692 |
| Private placement (note 10a) | NaN | 0 | 4,988 | NaN |
| Net cash provided by investing activities | 69,959 | 5,368 | 368 | 20,927 |
| Issuance of common stock on exercise of stock options | 8,717 | 6,825 | 7,923 | 2,156 |
| Issuance of common stock through employee stock purchase plan | 607 | 0 | 881 | 544 |
| Purchases of common stock for retirement | 76,151 | 25,479 | 16,216 | NaN |
| Proceeds from sale of future royalties | 250,000 | NaN | NaN | NaN |
| Deferred financing costs | NaN | NaN | 28 | 65 |
| Deferred financing fees | NaN | 181 | NaN | NaN |
| Payments for transaction costs related to sale of future royalties | 4,387 | NaN | NaN | NaN |
| Net cash provided by financing activities | 178,786 | -18,742 | -2,452 | 2,635 |
| Effect of exchange rate changes on cash and cash equivalents | 98 | -44 | 77 | -78 |
| Net change in cash and cash equivalents | 203,125 | -23,677 | -33,419 | 32,150 |
| Cash and cash equivalents, beginning of period | 41,157 | 64,834 | 66,103 | NaN |
| Cash and cash equivalents, end of period | 244,282 | 41,157 | 64,834 | NaN |